Selected Antiarrhythmics/Selected Protease Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Darunavir, lopinavir-ritonavir, or ombitasvir-paritaprevir-ritonavir may slow down how quickly your liver processes amiodarone or quinidine.
What might happen:
The amount of amiodarone or quinidine in your blood may increase. This may increase your risk of an irregular heartbeat or other adverse effects.
What you should do about this interaction:
Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to check the amount of your heart rhythm medicine (antiarrhythmic) in your blood. Your doctor may want to change the dose of your antiarrhythmic. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes, ringing in the ears or tremors.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Prezista (darunavir) US prescribing information. Janssen Therapeutics March, 2023.
- 2.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline March, 2019.
- 3.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories December, 2019.
- 4.Viekira Pak (ombitasvir, paritaprevir, and ritonavir; dasabuvir) US prescribing information. AbbVie Inc. December, 2019.
- 5.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 6.Prezista (darunavir) Canadian prescribing information. Jannsen-Ortho June, 2008.
- 7.Prezista (darunavir) UK Summary of product characteristics. Janssen-Cilgat LTD August 8, 2008.
- 8.Telzir (fosamprenavir calcium) Canadian product monograph. ViiV Healthcare ULC February 11, 2014.
- 9.Telzir (fosamprenavir calcium) UK summary of product characteristics. GlaxoSmithKline UK October 18. 2013.
- 10.Kaletra (lopinavir/ritonavir) Canadian prescribing information. Abbott Limited May 22, 2019.
- 11.Kaletra (lopinavir/ritonavir) UK summary of product characteristics. Abbott Laboratories, Limited July 11, 2008.
- 12.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult- and-adolescent-arv/whats-new March 23, 2023.
- 13.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.